Baloxavir Marboxil Powder CAS NO.1985605-59-1
CAS NO：1985605-59-1
Detection method: HPLC
Active ingredients: Baloxavir marboxil
Product Description: White to off white crystalline powder
Product Usage: Antiinfluenza Virus Drug
Product packaging: 1mg/bottle; 10 bottles/box
Product storage: Sealed, away from light, dry and stored at room temperature of 20-25 ℃, not frozen
Shelf life: 24 months
Products Description
Bivalirudin with high purity from Tihealth
Our production of Bivalirudin focuses on high purity, high quality, and high content, strictly following the international pharmacopoeia (USP/NF, EP, ChP) and GMP standards. The purity has been verified by HPLC and mass spectrometry, and the total impurity content is less than 0.1%.
This product is designed specifically for cardiovascular intervention therapy (PCI) and acute coronary syndrome (ACS), directly inhibiting thrombin without relying on antithrombin III, significantly reducing the risk of bleeding (especially intracranial hemorrhage), shortening postoperative recovery time, and avoiding the risk of heparin induced thrombocytopenia (HIT).
Based on clinical verification, it is safer than traditional methods in acute coronary intervention surgery, and does not require frequent monitoring of coagulation function, meeting the high standard requirements of pharmaceutical companies, medical institutions, and CRO companies. It provides stable batch quality and compliant solutions, and helps with precise anticoagulation practices in the field of cardiovascular therapy.
Products Function
1. Shortening the course of influenza: Clinical trials have shown that it can significantly reduce the duration of influenza symptoms (such as fever, cough, fatigue, etc.), with an average reduction of 1 day.
2. Reduce viral load: Quickly inhibit influenza virus replication and lower nasopharyngeal viral load.
3. Reduce the risk of complications: may lower the incidence of serious complications such as influenza related pneumonia.
Intended for:
Influenza patients aged 12 and above (best results achieved within 48 hours of symptom onset).
Both influenza A and B viruses are effective.
Mechanism of action
1. Target:
Influenza virus RNA polymerase (CAP dependent endonuclease).
This enzyme is a key protein for viral replication, responsible for "hijacking" the host cell's RNA promoter to synthesize viral RNA.
2. Process of action:
Prodrug activation: After oral administration, it is converted into the active metabolite Baloxavir in the body.
Inhibition of viral replication: Balosevir binds to viral RNA polymerase, blocking its function of "cutting" the host cell RNA promoter.
Inhibit the synthesis of viral mRNA, thereby preventing viral genome replication.
3. Differences from traditional medicines:
Unlike oseltamivir (a neuraminidase inhibitor), it belongs to a completely new mechanism of action.
Products Aplication
1. Treatment of influenza: Used for antiviral therapy in the early stages of symptoms (within 48 hours), especially for patients who cannot tolerate oseltamivir.
2: Potential extended use:
Preventive treatment: Study and explore its application in post exposure prevention of influenza (more clinical data support is needed).
High risk groups: such as elderly people, chronic disease patients, and those at high risk of influenza complications (need to be evaluated by a doctor).
Product advantages
1. Single dose oral administration
2. Quick onset
3. Potential for drug resistance
4. Good safety
Product Comparison
|
Characteristics |
Mabaloxavir |
Oseltamivir |
|
Mechanism of action |
Inhibition of RNA polymerase (CAP dependent) |
Inhibition of neuraminidase |
|
Medication method |
Single oral dose (20-40mg) |
Twice daily for 5 consecutive days (75mg/time) |
|
Effective speed |
Significant reduction in viral load within 24 hours |
Effective within 48 hours |
|
Drug resistance |
Effective against oseltamivir resistant viruses |
Some virus strains are resistant |
|
Compliance |
High (single dose) |
Moderate (requires multiple doses) |
Summary:
Baloxavir Marboxil Powder is an innovative oral antiviral drug for the treatment of influenza. With its single-dose, rapid onset and unique mechanism of action, it has made significant progress in the field of influenza treatment. Its advantages lie in simplifying the medication process, reducing the risk of drug resistance, and providing safer treatment options for high-risk groups.
Hot Tags: Baloxavir Marboxil Powder CAS NO.1985605-59-1, China Baloxavir Marboxil Powder CAS NO.1985605-59-1 manufacturers, suppliers, factory, calcium d3 powder, cracked wall chlorella, fermented chlorella, saccharomyces cerevisiae beta glucan, spirulina and chlorella powder, yeast beta glucans
You Might Also Like
Send Inquiry